Peptide Regulations Are Changing: What We Can and Can't Offer Right Now

If you've been following peptides at all over the last few years, you've watched a strange thing happen. The science got genuinely interesting, the marketing got completely out of hand, and the regulations lagged behind both. That gap is now closing, and I want to be straightforward with my patients about what that means.

I'm Dr. Farhan Abdullah, an internal medicine physician and Medical Director of Magnolia Functional Wellness in Southlake. This post exists for one reason: the legal status of compounded peptides is actively shifting, and I'd rather you hear an accurate version from me than a promotional version from someone selling vials online.

Short version up front. Several compounded peptide substances are under formal FDA review right now. Nothing has been approved yet. Until that changes, we're limiting what we offer and what we write about to peptide medications that already carry FDA approval. Here's the fuller picture.

What Actually Happened in July 2026

In late July, the FDA's Pharmacy Compounding Advisory Committee met over two days to evaluate a group of peptide substances. The question in front of them was narrow but consequential: should these substances be added to what's called the Section 503A Bulk Drug Substances List?

That list matters more than its dull name suggests. Under Section 503A of the Federal Food, Drug, and Cosmetic Act, a traditional compounding pharmacy can only prepare a medication from a bulk substance if that substance meets one of a few conditions. It has to be a component of an FDA-approved drug product, or the subject of a USP or National Formulary monograph, or appear on that 503A list. If a substance clears none of those bars, a compounding pharmacy has no lawful path to prepare it, regardless of how promising the research looks.

The committee reviewed the evidence and voted to recommend most of the substances under consideration for inclusion. That sounds like good news for peptide access, and eventually it might be. But a recommendation is not a rule, and the distinction is the entire point of this article.

Why a Recommendation Isn't Permission

This is where a lot of clinics are going to get themselves in trouble, and where patients are going to get misled.

The Pharmacy Compounding Advisory Committee is exactly what its name says: advisory. It reviews scientific evidence and gives the FDA its opinion. It doesn't write regulations, and it can't change federal law. The FDA holds all of the actual decision-making authority.

If the agency decides to act on those recommendations, the process from here is long and public. It generally starts with a Notice of Proposed Rulemaking published in the Federal Register, identifying which substances the FDA is considering adding. That proposal opens a public comment period, typically 60 to 90 days, where physicians, pharmacies, manufacturers, and anyone else can weigh in. Only after the agency reviews those comments does it decide whether to publish a final rule. The regulatory framework changes at that last step, and not one minute before.

So where does that leave things today? The substances discussed in July remain off the 503A list. They aren't the subject of applicable USP or NF monographs. They aren't components of FDA-approved drug products. Which means they remain ineligible for routine compounding under the rules currently in effect.

There's one more wrinkle worth knowing. The July meetings addressed 503A compounding pharmacies only, which are your traditional state-licensed pharmacies filling patient-specific prescriptions. They did not address 503B outsourcing facilities, which operate under an entirely separate section of the law. Even if the FDA eventually adds a substance to the 503A list, that wouldn't automatically make it available through a 503B facility. Different framework, different requirements.

What This Means for Magnolia Functional Wellness

We're going to operate according to the rules that exist today, not the rules that might exist next year. That's the whole policy.

Practically, that means we've pulled back on discussing and offering compounded peptides that don't currently have a lawful compounding pathway. Some of these have interesting preliminary research behind them. A few have research I find genuinely compelling. That isn't the question. The question is whether there's a legal basis to prepare and prescribe them right now, and for several popular substances the honest answer is no.

I understand this is frustrating if you've been reading about these compounds or hearing about them from friends. I'd rather frustrate you than mislead you. Clinics that keep marketing substances with no compounding pathway aren't being bold, they're accumulating regulatory risk and passing the consequences to their patients when supply disappears or an enforcement letter arrives.

The Peptide Medications We Do Offer

Here's what often gets lost in this conversation: several of the most effective peptide medications in modern medicine are fully FDA-approved, and we prescribe them every week.

• Semaglutide and tirzepatide. Both are peptides. Both carry FDA approval. Both have produced the most substantial weight loss and metabolic outcomes we've seen from any pharmacologic approach, backed by large randomized trials rather than anecdote.
• Tesamorelin. An FDA-approved growth hormone releasing hormone analog, studied in randomized controlled trials for reduction of visceral adipose tissue in specific populations.
• Bremelanotide. FDA-approved for hypoactive sexual desire disorder in premenopausal women, and a genuinely different mechanism from anything else in that space.
• Oxytocin and hCG. Both peptide hormones with established approved uses and long clinical track records.

That's not a consolation prize. If your goals involve metabolic health, weight, body composition, or sexual wellness, the approved options are where the strongest evidence lives anyway. I'd rather build your protocol on molecules with real trial data and a clean regulatory footing than on something whose main credential is being talked about a lot.

Why You Should Check Back Weekly

The reason I'm asking you to treat this as a living page rather than a one-time announcement is that this situation genuinely could change, and possibly within the next several months.

If the FDA moves forward with rulemaking, there will be a proposed rule, a public comment window, and eventually a final decision. Any of those steps could shift what's legitimately available. We're monitoring the Federal Register and the FDA's published 503A list directly, and we'll update this page as things move. When a substance actually becomes eligible, we'll say so here, and we'll explain what the evidence does and doesn't support before anyone starts a protocol.

What I'd ask in the meantime is a little skepticism toward anyone selling you certainty right now. If a clinic or an online vendor is telling you a peptide was just approved, ask them to point at the final rule. If they can't, they're describing a recommendation and calling it permission.

Regulatory ground shifting under a promising field is uncomfortable, but it's also how a field grows up. The peptides that come through this process with a lawful pathway will be on far firmer footing than the gray market ever was. Until then, we'll practice according to the rules as written, and I'll keep you posted here as they change. If you want to talk through which options are legitimately available to you today, that conversation is always open at Magnolia Functional Wellness in Southlake.

By Dr. Farhan Abdullah, DO | Medical Director, Magnolia Functional Wellness | Southlake, TX

This article reflects the regulatory landscape as of August 2026 and is for educational purposes, not individual medical advice. Regulatory status can change. Verify current information with the FDA or your physician before making treatment decisions.